Treatment of MM cells with non-targeting (NT) or ILF2 targeting oligonucleotide antisenses (ASOs). Treatment of MM cells with non-targeting (NT) or ILF2 targeting oligonucleotide antisenses (ASOs)

To gain insights into the molecular mechanisms by which myeloma cells overcome ILF2 ASO-induced DNA damage activation, we performed bulk RNA sequencing (RNA-seq) analysis of ASO-treated KMS11 and JJN3 cells at early (1 week) and late (3 weeks) treatment time points. Overall design: MM cells were treated with NT (control) or ILF2 ASOs for 1 or 3 weeks to evaluate whether they could overcome ILF2 ASO-induced DNA damage. Three replicates were included for each.